SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Patients with pathologically confirmed selected tumor types (at site or centrally);
Mandatory availability of adequate human biological material (HBM);
Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
Age ≥ 12 years;
None
Patients with pathologically confirmed selected tumor types.
Cohort
Prospective
RP-1828 IMMUcan
GeneticWES, lcWGS and RNAseq, multiplex IF and IMC
RP-1759 AYA/TYA
GeneticWES, RNAseq and EPIC array
RP-1843 Arcagen
GeneticNGS panel
RP-1920 BioRadon
GeneticNGS panel
2148 MRD
GeneticctDNA detection and WES
To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care
material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.
To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future;
To investigate the molecular pathways related to the development of specific tumors from a biological point of view;
To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally;
To collect large series of homogeneous clinical data to analyse the disease course and treatment performed;
Click on the lead sponsor to view all of their trials.